amprenavir


Also found in: Dictionary, Wikipedia.
Related to amprenavir: Fosamprenavir, Atazanavir

amprenavir

 [am-pren´ah-vir]
an HIV protease inhibitor used in the treatment of human immunodeficiency virus (HIV) infection; administered orally.

amprenavir

/am·pren·a·vir/ (am-pren´ah-vir) an HIV protease inhibitor used in the treatment of HIV-1 infection.

amprenavir

an antiviral (protease inhibitor).
indication It is used to treat HIV in combination with other antiretroviral agents.
contraindication Known hypersensitivity prohibits its use.
adverse effects Life-threatening side effects include Stevens-Johnson syndrome and acute hemolytic anemia. Other serious adverse effects include new-onset diabetes, hyperglycemia, and exacerbation of preexisting diabetes mellitus. Common side effects include diarrhea, abdominal pain, nausea, paresthesia, and rash.

amprenavir

A protease inhibitor used with other antiretrovirals for managing HIV-1 (e.g., nelfinavir, indinavir or saquinavir).

Adverse effects
Nausea, vomiting, diarrhoea, headache, perioral paraesthesias, gastric discomfort, rash, hyperglycaemia, diabetes, acute haemolytic anaemia, spontaneous bleeding in haemophiliacs, fat redistribution.

amprenavir

AIDS A protease inhibitor in clinical trials for treating HIV, used in combination with other protease inhibitors–eg, nelfinavir, indinavir, or saquinavir Adverse effects N&V, diarrhea, headache, perioral paresthesias, stomach discomfort, rash; other effects include hyperglycemia, DM, acute hemolytic anemia, spontaneous bleeding in hemophiliacs, and fat redistribution. See AIDS, Combination therapy, HIV, Protease inhibitor.

amprenavir

A protease inhibitor drug used to treat HIV infections. A brand name is Agenerase.
References in periodicals archive ?
A previous study had shown a 30% reduction in blood concentration of amprenavir when Zantac (another drug for reducing stomach acidity) was given one hour before Lexiva [2].
LEXIVA is contraindicated in patients with previously demonstrated clinically significant hypersensitivity to any of the components of this product or to amprenavir.
No relevant effects of TDF on plasma amprenavir (APV) PK were demonstrated when once daily TDF 300mg was given in combination with once daily LEXIVA/r 1400/100 or 1400/200.
Comparator PIs included lopinavir, saquinavir, amprenavir and indinavir; however, lopinavir was selected for 50% of patients in the comparator PI arm.
FDA Pregnancy Categories of Antiretroviral Drugs Nucleoside Nonnucleside Reverse Reverse Trancriptase Trancriptase Protease Category Inhibitors Inhibitors Inhibitors B didanosine atazanavir emtricitabine nelfinavir tenofovir ritonavir saquinavir C abacavir efavirenz amprenavir lamivudine (3TC) nevirapine undinavir stavudine (d4T) lopinavir/ritonavir zalcitadine (ddC) zidovudine (AZT) D Fusion Miscellaneous Category Inhibitors Agents B enfurtide C D Hydroxyurea Note: No antiretroviral agents in pregnancy category A or X.
Lexiva is converted into amprenavir (Agenerase), a previously approved protease inhibitor, in the body.
Researchers in Denmark report that the protease inhibitor amprenavir (Agenerase) lowers the levels of delavirdine (Rescriptor).
When LEXIVA was simultaneously co-administered with Nexium there was no effect on amprenavir (the active molecule LEXIVA) steady-state plasma levels.
The Food and Drug Administration (FDA) has approved an official recommended dose for combining the protease inhibitors amprenavir (Agenerase) and ritonavir (Norvir).
Patients with a current regimen can continue the regimen unless the drugs have a specific contraindication in pregnancy such as efavirenz and amprenavir, which are associated with congential abnormalities.
T20-206 was an open label, randomized Phase II controlled study of T-20 comparing three doses of T-20 in combination with a regimen of oral antiretrovirals (abacavir, amprenavir, ritonavir and efavirenz) in 71 nNRTI-naive and protease inhibitor (PI)- and nucleoside reverse transcriptase inhibitor (NRTI)-experienced HIV patients.
These data complement findings from a clinical study of LEXIVA/r in protease inhibitor experienced patients wherein plasma amprenavir trough concentrations were similar for subjects receiving tenofovir as compared to subjects not receiving tenofovir," said Doug Manion, M.